Special Issue

APOBECs and Virus Restriction

Message from the Guest Editor

The APOBEC3 viral restriction factors exist in all placental mammals, with different numbers of APOBEC3s in each organism. Human APOBEC3s were first discovered to inhibit the retrovirus HIV-1 but can also inhibit pararetroviruses, human herpesviruses, coronaviruses, polyomaviruses, and perhaps others. Current knowledge gaps include how the APOBEC3 enzymes access the diverse viral genomes during the lifecycle, whether the seven primate APOBEC3 enzymes function redundantly or are specialized to restrict specific viruses, the balance between APOBEC3induced viral restriction, viral evolution, and host genomic damage in each virus system, and the counteraction mechanisms of all the viruses to APOBEC3s. This Special Issue invites articles and reviews that focus on mechanisms of APOBEC3 restriction of viruses, virus counteraction mechanisms, structural biology or biochemistry as related to virus restriction, and the extent to which APOBEC mutagenesis contributes to virus restriction, virus evolution, or host genomic damage.

Guest Editor

Dr. Linda Chelico

College of Medicine, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada

Deadline for manuscript submissions

closed (31 October 2020)



Viruses

an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/46973

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

mdpi.com/journal/ viruses





Viruses

an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Viruses* (ISSN 1999-4915). *Viruses* is published in open access format—research articles, reviews and other content are released on the internet immediately after acceptance. The scientific community and the general public have unlimited free access to the content as soon as it is published. As an open access journal, *Viruses* is supported by the authors or their institutes by payment of article processing charges (APC) for accepted papers. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).

